Two-Year Clinical Outcomes of the CONSEQUENT Trial: Can Femoropopliteal Lesions be Treated with Sustainable Clinical Results that are Economically Sound?

CardioVascular and Interventional Radiology

Volumn 41, Issue 7, 2018, Pages 1008-1014

  Albrecht, Thomas ^a   Waliszewski, Matthias ^b,c   Roca, Catherine ^d,e   Redlich, Ulf ^f   Tautenhahn, Jörg ^f   Pech, Maciej ^g   Halloul, Zuhir ^g   Gögebakan, Özlem ^a   Meyer, Dirk Roelfs ^h   Gemeinhardt, Ines ^c   Zeller, Thomas ⁱ   Müller Hülsbeck, Stefan ^j   Ott, Ilka ^k   Tepe, Gunnar ^l  

^a VIVANTES HOSPITAL   (Germany)

^b B Braun Melsungen AG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e FRESENIUS UNIVERSITY OF APPLIED SCIENCES   (Germany)

^f Klinikum Magdeburg   (Germany)

^g UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^h St Hubertus Hospital   (Germany)

ⁱ UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^j University Heart Center Bad Krozingen ^*  (Germany)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^l Klinikum Rosenheim   (Germany)

more..

Author keywords

Cost efficacy; Drug coated balloon catheter; Femoropopliteal lesions; Peripheral artery occlusive disease; Target lesion revascularization

Indexed keywords

PACLITAXEL; RESVERATROL; BIOCOMPATIBLE COATED MATERIAL;

AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMORAL ARTERY; GERMANY; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VASCULAR PATENCY; WALKING; ANGIOGRAPHY; CLINICAL TRIAL; DEVICES; DIAGNOSTIC IMAGING; ECONOMICS; FEMALE; KAPLAN MEIER METHOD; MALE; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR;

AGED; ANGIOGRAPHY; ANGIOPLASTY, BALLOON; COATED MATERIALS, BIOCOMPATIBLE; FEMALE; FEMORAL ARTERY; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85044450207     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-018-1940-1     Document Type: Article

References (20)

1. Tepe G, Gögebakan Ö, Redlich U, et al. Angiographic and clinical outcomes after treatment of femoro-popliteal lesions with a novel paclitaxel-matrix-coated balloon catheter. Cardiovasc Intervent Radiol. 2017;40(10):1535–44.
2. Herten M, Torsello GB, Schönefeld E, Stahlhoff S. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease. Vasc Health Risk Manag. 2016;12:341–56.
3. Laird JR, Schneider PA, Tepe G, et al. IN.PACT SFA trial investigators. Durability of Treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66(21):2329–38.
4. Salisbury AC, Li H, Vilain KR, et al. Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II Trial. JACC Cardiovasc Interv. 2016;9(22):2343–52.
5. Pietzsch JB, Geisler BP, Garner AM, Zeller T, Jaff MR. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany. Catheter Cardiovasc Interv. 2014;84(4):546–54.
6. German DRG System. http://g-drg.de/G-DRG-System_2017/Fallpauschalen-Katalog2/Fallpauschalen-Katalog_2017. Accessed 15 Nov 2017.
7. ® Please OTW: Masters Thesis. Welsh School of Pharmacy, Cardiff University in collaboration with Hochschule Fresenius, June 2017.
8. Diehm N, Diehm C, Kalka C, Dick F. Peripheral endovascular revascularization trials: high noon for uniform reporting standards. Acta Chir Belg. 2008;108(4):382–5.
9. Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014;11(1):13–23.
10. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689–99.
11. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13):1358–65.
12. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831–40.
13. Rosenfield K, Jaff MR, White CJ, et al. LEVANT 2 investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145–53.
14. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7(1):10–9.
15. Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Duda S. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv. 2015;86(2):278–86.
16. Schroeder H, Werner M, Meyer DR, et al. ILLUMENATE EU RCT investigators. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon). Circulation. 2017;135(23):2227–36.
17. Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22(1):14–21.
18. Jia X, Zhang J, Zhuang B, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial. JACC Cardiovasc Interv. 2016;9(18):1941–9.
19. Katsanos K, Spiliopoulos S, Paraskevopoulos I, Diamantopoulos A, Karnabatidis D. Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther. 2016;23(2):356–70.
20. Krishnan P, Faries P, Niazi K, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation. 2017;136(12):1102–13.